In its mid-year performance report for 2024, CKLife Sciences announced that for the six months ended June 30, 2024, the company recorded unaudited profit attributable to shareholders of approximately HKD 1 million, down 97% from the same period of last year. The profit before tax was HKD 174.5 million, but most of it was offset by financial costs. The board of directors decided not to pay interim dividends. The company also announced the sale of Balranald vineyard land and water licenses in Australia, expecting to record sales revenue of approximately AUD 8.2 million. CKLife Sciences focuses on the research and development of cancer therapies and early detection programs, and invests in an artificial intelligence cancer vaccine discovery platform. The company's healthcare product business performed steadily, while agricultural-related businesses lagged behind last year due to high inventory and pressure on demand. Looking ahead, the company will continue to invest in medical and diagnostic research fields, and is optimistic about improving its business performance in the second half of the year.

In its mid-year performance report for 2024, CKLife Sciences announced that for the six months ended June 30, 2024, the company recorded unaudited profit attributable to shareholders of approximately HKD 1 million, down 97% from the same period of last year. The profit before tax was HKD 174.5 million, but most of it was offset by financial costs. The board of directors decided not to pay interim dividends. The company also announced the sale of Balranald vineyard land and water licenses in Australia, expecting to record sales revenue of approximately AUD 8.2 million. CKLife Sciences focuses on the research and development of cancer therapies and early detection programs, and invests in an artificial intelligence cancer vaccine discovery platform. The company's healthcare product business performed steadily, while agricultural-related businesses lagged behind last year due to high inventory and pressure on demand. Looking ahead, the company will continue to invest in medical and diagnostic research fields, and is optimistic about improving its business performance in the second half of the year.